487 related articles for article (PubMed ID: 15130417)
1. [Hyperhomocysteinemia, oxidative stress and microinflammation in chronic renal failure: their roles in atherogene].
Yu YM; Hou FF; Zhang X; Zhou H; Liu ZQ
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):292-5. PubMed ID: 15130417
[TBL] [Abstract][Full Text] [Related]
2. [The role of hyperhomocysteinemia on atherosclerosis in patients with chronic renal failure].
Yu Y; Hou F; Zhou H; Yang Y; Zhang X; Yang L; Hu M
Zhonghua Nei Ke Za Zhi; 2002 Aug; 41(8):517-21. PubMed ID: 12421497
[TBL] [Abstract][Full Text] [Related]
3. [Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease].
Yang XB; Hou FF; Wu Q; Zhou H; Liu ZR; Yang Y; Zhang X
Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):342-6. PubMed ID: 16009002
[TBL] [Abstract][Full Text] [Related]
4. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.
Stenvinkel P; Heimbürger O; Paultre F; Diczfalusy U; Wang T; Berglund L; Jogestrand T
Kidney Int; 1999 May; 55(5):1899-911. PubMed ID: 10231453
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between cardiovascular complication and inflammation, oxidative stress of patient with maintenance hemodialysis].
Zuo C; Qiu HY; Li Z; Xie XS; Fan JM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 39(1):119-21, 129. PubMed ID: 18390217
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine and carotid atherosclerosis in chronic renal failure--the confounding effect of renal function.
Leskinen Y; Lehtimäki T; Loimaala A; Huhtala H; Salenius JP; Oja SS; Saha H
Atherosclerosis; 2004 Aug; 175(2):315-23. PubMed ID: 15262188
[TBL] [Abstract][Full Text] [Related]
7. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
[TBL] [Abstract][Full Text] [Related]
8. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria.
Ozdemir G; Ozden M; Maral H; Kuskay S; Cetinalp P; Tarkun I
Ann Clin Biochem; 2005 Mar; 42(Pt 2):99-104. PubMed ID: 15829117
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
[TBL] [Abstract][Full Text] [Related]
11. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.
McGregor DO; Dellow WJ; Lever M; George PM; Robson RA; Chambers ST
Kidney Int; 2001 Jun; 59(6):2267-72. PubMed ID: 11380830
[TBL] [Abstract][Full Text] [Related]
12. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia.
Mezzano D; Pais EO; Aranda E; Panes O; Downey P; Ortiz M; Tagle R; González F; Quiroga T; Caceres MS; Leighton F; Pereira J
Kidney Int; 2001 Nov; 60(5):1844-50. PubMed ID: 11703602
[TBL] [Abstract][Full Text] [Related]
13. IL-18 is involved in vascular injury in end-stage renal disease patients.
Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease.
Haraki T; Takegoshi T; Kitoh C; Kajinami K; Wakasugi T; Hirai J; Shimada T; Kawashiri M; Inazu A; Koizumi J; Mabuchi H
Clin Nephrol; 2001 Aug; 56(2):132-9. PubMed ID: 11522090
[TBL] [Abstract][Full Text] [Related]
15. Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values "in normal range".
Tutal E; Sezer S; Bilgic A; Aldemir D; Turkoglu S; Demirel O; Ozdemir N; Haberal M
Transplant Proc; 2007 Dec; 39(10):3035-40. PubMed ID: 18089316
[TBL] [Abstract][Full Text] [Related]
16. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy.
Suliman ME; Stenvinkel P; Heimbürger O; Bàràny P; Lindholm B; Bergström J
Am J Kidney Dis; 2002 Sep; 40(3):480-8. PubMed ID: 12200798
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
Fellah H; Feki M; Hsairi M; Sanhaji H; Kaabachi N; Ben Abdallah T; Massy ZA; Ben Maiz H; Lacour B; Mebazaa A
Clin Chem Lab Med; 2003 May; 41(5):675-80. PubMed ID: 12812266
[TBL] [Abstract][Full Text] [Related]
18. [Characteristics of hyperhomocysteinemia in dialysis patients].
Lovcić V; Kes P; Reiner Z
Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
[TBL] [Abstract][Full Text] [Related]
19. Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results.
Zoungas S; Branley P; Kerr PG; Ristevski S; Muske C; Demos L; Atkins RC; Becker G; Fraenkel M; Hutchison BG; Walker R; McNeil JJ; McGrath BP
Nephrology (Carlton); 2004 Jun; 9(3):130-41. PubMed ID: 15189174
[TBL] [Abstract][Full Text] [Related]
20. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
